Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675515 | 0.89 | MAPT (0.65) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL441419 | 0.89 | TTR (0.71) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL9797021 | 0.86 | HDAC6 (0.65) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL13135790 | 0.85 | HDAC6 (0.63) | TTRALBMAOACNR1DRD1 | |
| Hydrochloric Acid SCHEMBL17985190 | 0.84 | HDAC6 (0.62) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL445014 | 0.84 | HDAC6 (0.74) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL444191 | 0.83 | MAOA (0.80) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL28380321 | 0.81 | MAPT (0.50) | HDAC6MAPTHDAC3HDAC1HDAC8 | |
| SCHEMBL1675525 | 0.81 | HDAC6 (0.63) | TTRALBMAOACNR1DRD1 | |
| SCHEMBL14326101 | 0.81 | HDAC6 (0.70) | TTRALBMAOACNR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587821-B1 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2008-08-20 | — | — | EP | claimed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | claimed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | claimed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | claimed |
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20140134753-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| CN-101413143-B | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST | 2013-09-18 | — | — | CN | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1988397-B1 | COMPOSITIONS AND USES FOR STABILISING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2011-09-14 | — | — | EP | disclosed |
| EP-2325651-A2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-05-25 | — | — | EP | disclosed |
| EP-1587821-A4 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | TTR 1/4885ALB 26/4885MAOA 1980/4885 |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | TTR 1/4885ALB 26/4885MAOA 1980/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | TTR 1/4885ALB 10/4885MAOA 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.